MedTrace Logo

A Study of Nopan Treatment of Acute Suicidality

NCT01046851 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-01-04

No results posted yet for this study

Summary

Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.

Conditions

Interventions

DRUG

Nopan

Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)

DRUG

Placebo

Placebo in a manner similar to the active comparator

Sponsors & Collaborators

  • University of Haifa

    collaborator OTHER

  • Prof. Yoram Yovell

    lead OTHER

Principal Investigators

  • Yoram Yovell, MD, PhD · University of Haifa, Institute for the Study of Affective Neuroscience

  • Mordechai Masiah, MD · Abarbanel MHC

  • Jack Asherov, MD · Edith Wolfson Medical Center

  • Nathaniel Laor, MD, PhD, Director · Tel Aviv- Brill Community Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046851 on ClinicalTrials.gov